Kimia Jazi

Dr. Kimia Jazi


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2025 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
ADAmir Dayhimi
Amir Dayhimi
KJKimia Jazi
Kimia Jazi
ABAsiye Bigdeli
Asiye Bigdeli
FFFatemeh Farhoudi
Fatemeh Farhoudi
MEMohamadreza Erfanimanesh
Mohamadreza Erfanimanesh
Hamidreza Pazoki ToroudiHamidreza Pazoki Toroudi
Hamidreza Pazoki Toroudi
Introduction: Immunotherapy approaches have improved by Immune check point inhibitors such as PD-1, CTLA-4, and PD-L1 inhibitors. However, the response to immunotherapy varies widely among patients due to various factors. Co-administration of probiotics with ICIs has become a promising strategy to improve therapeutic outcomes. This review evaluates the impact of environmental factors and life style on cancer pathophysiology, outcome of disease, and response to the treatment. It evaluates the role of probiotics in modulating immune responses and the synergistic interaction of probiotics with immunotherapy. Methods: We conducted a comprehensive systematic review of clinical and preclinical studies to assess the effects of probiotics on immunotherapy outcomes. Studies were selected based on their focus on probiotics’ role in immune response modulation and interaction with ICIs. Data from trials involving patients with varying responses to immunotherapy, including those with prior resistance, were analyzed to explore the probiotic-enhanced immunotherapy. Results: Gut microbiome has wide effects on immune responses through different pathways like production of short chain fatty acids (SCFAs), polysaccharide A, and indole-3-carbaldehyde. Also, probiotics found to enhance Anit-inflammatory responses and increase CD8+ T-cell activity, suggesting a synergistic effect with ICIs. Gut microbiota composition plays a key role in determining the effectiveness of immunotherapy, especially in treatment-resistant patients. For optimized treatment outcomes, personalized probiotics tailored to individual's microbiota showed potential. Important challenges are treatment resistance and compromised mucosal integrity because of microbiome alterations. Effective drug delivery also remains as important barriers to common adoption. Conclusion: For immunotherapy outcomes improvement, immune responses modulation and gut microbiome diversity enhancement show probiotics important promise. Despite their potential, limitations must be addressed including treatment resistance and also delivery challenges. In order to maximize therapeutic benefits, personalized probiotic strategies have to be developed, and also the mechanisms by which probiotics improve ICI efficacy require elucidation through further research.

24 July 2025 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
HHHossein Hemmati
Hossein Hemmati
ALAmirhossein Larijani
Amirhossein Larijani
AMAmirabbas Mollaei
Amirabbas Mollaei
MAMohammad Amin Ashoobi
Mohammad Amin Ashoobi
ANAbolfazl Nikkhoy
Abolfazl Nikkhoy
KJKimia Jazi
Kimia Jazi

18 July 2023 in Clinical Case Reports
Verified
Journal Article
Open access
AAAlireza Arezoumand
Alireza Arezoumand
SNSahar Nazari
Sahar Nazari
KJKimia Jazi
Kimia Jazi
MBMohammad Bagherzade
Mohammad Bagherzade
MRMohammad Mehdi Riahi
Mohammad Mehdi Riahi
MMMaryam Masoumi
Maryam Masoumi
Key Clinical Message: Myopathy‐related symptoms are rare manifestations of hypothyroidism. Clinicians should consider hypothyroid myopathy as one of the possible diagnoses for patients with proximal weaknesses. Myopathy‐related symptoms are rare manifestations of hypothyroidism. Clinicians should consider hypothyroid myopathy as one of the possible diagnoses for patients with proximal weaknesses. We report a 34‐year‐old woman, presenting with a new atypical musculoskeletal manifestation of hypothyroidism mimicking polymyositis.

11 August 2025 in Current Gastroenterology Reports
Verified
Journal Article
Closed access
PLParsa Lorestani
Parsa Lorestani
FFFerdos Faghihkhorasani
Ferdos Faghihkhorasani
HSHomina Saffar
Homina Saffar
BDBehnam Darabi
Behnam Darabi
YTYasaman Tavakoli
Yasaman Tavakoli
KJKimia Jazi
Kimia Jazi

16 October 2025 in BMC Surgery
Verified
Journal Article
Open access
PDF file
KJKimia Jazi
Kimia Jazi
ALAmirhossein Larijani
Amirhossein Larijani
MRMarzieh Rahimi
Marzieh Rahimi
ERErfan Rajabi
Erfan Rajabi
PDPouya Karami Dehkordi
Pouya Karami Dehkordi
BSBabak Sabet
Babak Sabet
Pilonidal disease is a common sacrococcygeal cyst or sinus that can significantly impact patients’ quality of life, necessitating an analysis of evolving treatments to optimize patient outcomes. This review compares traditional and minimally invasive techniques focusing on laser ablation, in treating pilonidal cysts, focusing on each method’s effectiveness, recovery time, recurrence rates, complications, cosmetics, and costs. We conducted a comprehensive assessment of literature exploring PubMed, Scopus, Web of Science, Google Scholar, and Embase for studies comparing traditional surgical techniques including traditional excision with open and closed healing, flap reconstructions, with minimally invasive procedures focusing on laser-assisted. Although traditional surgical techniques were practical, but they were associated with a relatively high risk of wound complications, recurrence, extended healing periods, and poor cosmetics. Laser techniques showed promising results in reducing hospital stays (for at most 3 h vs. days), postoperative pain, and recurrence rates, with healing rates up to 97%. However, laser methods may be less effective in severe or complicated cases, and they have higher costs. Laser-assisted techniques offer a less invasive option compared to traditional surgery, with greater patient fulfillment. However, additional research is needed to optimize laser procedures, especially in complex cases, and to establish long-term outcomes. For simpler pilonidal cysts, laser treatments are a promising option that could eventually replace traditional surgery as the standard of care.

19 October 2023
Verified
Preprint
Open access
PDF file
KJKimia Jazi
Kimia Jazi
MRMahnaz Rahimi
Mahnaz Rahimi
FHFatemeh Hasani
Fatemeh Hasani
MSMaryam Shirmohammadi
Maryam Shirmohammadi
MMMaryam Masoumi
Maryam Masoumi
Scleritis Following the booster shot of inactivated COVID-19 (Sinopharm) Vaccine in a 52-year-old WomanKimia Jazi1, Mahnaz Rahimi1, Fatemeh Hasani2, Maryam Shirmohammadi1, Maryam Masoumi3*1Student Research Committee, Faculty of Medicine, Medical University of Qom, Qom, Iran2 Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran3 Clinical Research of Development Center, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran